Lyndra Inc. and Global Drug Commercialization Center Announce Joint Venture to Develop Lyndra’s Ultra-long-acting Oral Dosage Form for Chinese Market
Lyndra Inc., an emerging biopharmaceutical company, today announced the formation of a joint venture with Global Drug Commercialization Center (GDCC) to commercialize Lyndra’s groundbreaking medicines in China. The partners held a public ribbon-cutting ceremony for the new Lyndra (China) Pharmaceuticals Co., Ltd. headquarters in Chengdu, China.
Lyndra is developing ultra-long-acting oral therapies that free patients of the need to take daily medications and drastically improve healthcare outcomes.
Printed from https://innovationblog.partners.org/lyndra-inc-and-global-drug-commercialization-center-announce-joint-venture-to-develop-lyndras-ultra-long-acting-oral-dosage-form-for-chinese-market · Published 07 Nov 2018
© PARTNERS HEALTHCARE. ALL RIGHTS RESERVED